Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

Simply Wall St.12-07

Key Insights Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 16 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489503022?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","is_english":true,"pubTime":"2024-12-07 02:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489503022","market":"us","top_or_hot":-1,"title":"Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake","media":"Simply Wall St.","content":"<div>\n<p>Key Insights\n\n Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to their trading decisions \n 50% of the business is held by the top 16 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zevra-therapeutics-inc-nasdaq-zvra-184822144.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-07 02:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zevra-therapeutics-inc-nasdaq-zvra-184822144.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights\n\n Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to their trading decisions \n 50% of the business is held by the top 16 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zevra-therapeutics-inc-nasdaq-zvra-184822144.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/zevra-therapeutics-inc-nasdaq-zvra-184822144.html","article_id":"2489503022","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489503022","pubTimestamp":1733510902,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to their trading decisions. 50% of the business is held by the top 16 shareholders. A look at the shareholders of Zevra Therapeutics, Inc.  can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 42% ownership. Put another way, the group faces the maximum upside potential .Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of Zevra Therapeutics.NasdaqGS:ZVRA Earnings and Revenue Growth December 6th 2024. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","QID":"纳指两倍做空ETF","BK4007":"制药","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","TQQQ":"纳指三倍做多ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","ZVRA":"Zevra Therapeutics","SQQQ":"纳指三倍做空ETF"},"translate_title":"Zevra Therapeutics，Inc.（纳斯达克：ZVRA）引起了持有42%股份的机构投资者的注意","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights\n\n Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to their trading decisions \n 50% of the business is held by the top 16 shareholders \n  Insiders have been buying lately  \n\n A look at the shareholders of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 42% ownership. Put another way, the group faces the maximum upside potential (or downside risk). \n Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. \n In the chart below, we zoom in on the different ownership groups of Zevra Therapeutics. \n See our latest analysis for Zevra Therapeutics \n\n\n\n  NasdaqGS:ZVRA Ownership Breakdown December 6th 2024\n \n\nWhat Does The Institutional Ownership Tell Us About Zevra Therapeutics?\n Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. \n As you can see, institutional investors have a fair amount of stake in Zevra Therapeutics. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zevra Therapeutics' earnings history below. Of course, the future is what really matters. \n\n\n\n  NasdaqGS:ZVRA Earnings and Revenue Growth December 6th 2024\n \n\n Our data indicates that hedge funds own 13% of Zevra Therapeutics. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Woodline Partners LP is the largest shareholder with 7.6% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 5.8% and 5.7%, of the shares outstanding, respectively. \n A closer look at our ownership figures suggests that the top 16 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. \n While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. \nInsider Ownership Of Zevra Therapeutics\n The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. \n I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. \n Shareholders would probably be interested to learn that insiders own shares in Zevra Therapeutics, Inc.. As individuals, the insiders collectively own US$30m worth of the US$490m company. This shows at least some alignment. You can  click here to see if those insiders have been buying or selling.  \nGeneral Public Ownership\n The general public, who are usually individual investors, hold a 39% stake in Zevra Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. \nNext Steps:\n While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified   1 warning sign for Zevra Therapeutics  that you should be aware of. \n But ultimately  it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. \nNB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489503022"}